Processa Pharmaceuticals, Inc.
PCSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | 0.05 | -0.00 | 0.31 |
| FCF Yield | -1.53% | -2.84% | -3.10% | -2.75% |
| EV / EBITDA | -64.55 | -18.47 | -29.96 | -29.47 |
| Quality | ||||
| ROIC | -59.81% | -64.42% | -79.61% | -154.53% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.01 | 0.58 | 0.96 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -53.47% | 16.83% | -21.45% | 37.66% |
| Safety | ||||
| Net Debt / EBITDA | 1.84 | 1.75 | 1.00 | 0.41 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |